The Oncologist-Patient Partnership

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and following chemotherapy.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for immunotherapy.